Publication Name	World Journal of Respirology
Manuscript ID	83640
Country	India

Received	2023-02-03 02:26
Peer-Review Started	2023-02-03 02:30
To Make the First Decision
Return for Revision	2023-02-21 06:38
Revised	2023-03-03 20:39
Second Decision	2023-05-08 03:12
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-05-08 07:56
Articles in Press	2023-05-08 07:56
Publication Fee Transferred
Edit the Manuscript by Language Editor	2023-05-02 18:44
Typeset the Manuscript	2023-05-26 01:07
Publish the Manuscript Online	2023-05-26 08:08

ISSN	2218-6255 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Minireviews
Article Title	Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail
Manuscript Source	Unsolicited Manuscript
All Author List	Jyoti Bajpai, Surya Kant, Ajay Kumar Verma and Akshyaya Pradhan
Funding Agency and Grant Number
Corresponding Author	Jyoti Bajpai, MD, Assistant Professor, Doctor, Doctor, Department of Respiratory Medicine, King George’s Medical University, E 1204 Shalimar Gallant Mahanagar , Lucknow 226003, India. jyotibajpai33@gmail.com
Key Words	SARS-CoV-2; Mild COVID-19; Antibodies; Risk factors
Core Tip	The coronavirus disease 2019 (COVID-19) pandemic is a severe public health emergency that necessitates the rapid development of novel medicines and viral detection technologies. Monoclonal antibodies against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have become an important target for the creation of therapeutic antibodies. The use of antibody cocktails is anticipated to be a key component of an efficient COVID-19 treatment plan because SARS-CoV-2 has a high mutation rate, particularly when subjected to the selection pressure of aggressively applied preventive vaccinations and neutralising antibodies.
Publish Date	2023-05-26 08:08
Citation	Bajpai J, Kant S, Verma AK, Pradhan A. Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail. World J Respirol 2023; 12(1): 1-9
URL	https://www.wjgnet.com/2218-6255/full/v12/i1/1.htm
DOI	https://dx.doi.org/10.5320/wjr.v12.i1.1

Full Article (PDF)	WJR-12-1.pdf
Full Article (Word)	WJR-12-1.docx
Manuscript File	83640_Auto_Edited-HZ-FilipodiaCL-JLW.docx
Answering Reviewers	83640-Answering reviewers.pdf
Audio Core Tip	83640-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	83640-Conflict-of-interest statement.pdf
Copyright License Agreement	83640-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	83640-Language certificate.pdf
Scientific Editor Work List	83640-Scientific editor work list.pdf
CrossCheck Report	83640-CrossCheck report.pdf
CrossCheck Report	83640-Peer-review(s).pdf